IMNN
Imunon Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$1.620
Kõrge
$1.620
Madal
$1.620
Maht
0.84M
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika
Seotud uudised
Life Sciences Investor Forum Agenda Announced for June 11th-12th
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th
LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D.,
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001's Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral presentation at ASCO 2025
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress LAWRENCEVILLE, N.J. , June
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc.
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading peer-reviewed journal
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc.
Seotud aktsiad
ATGE
Adtalem Global Education Inc.
MEC
Mayville Engineering Company Inc.
EVT
Eaton Vance Tax Advantaged Dividend Income Fund Common Shares of Beneficial Interest
ASO
Academy Sports and Outdoors Inc.
MPLN
MultiPlan Corporation
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.